Literature DB >> 18253698

Expression of TLR9 within human glioblastoma.

Yuxia Meng1, Michèle Kujas, Yannick Marie, Sophie Paris, Joëlle Thillet, Jean-Yves Delattre, Antoine F Carpentier.   

Abstract

Immunostimulating oligonucleotides containing CpG motifs (CpG-ODN) have shown promising antitumor activity in preclinical glioma models. CpG motifs are specifically recognized by the Toll-like receptor 9 (TLR9), mainly expressed in plasmacytoid dendritic cells (pDCs) and B cells. Expression of TLR9 within human glioma samples has not been investigated. As CpG-ODN is currently under clinical trials in glioma patients, we investigated whether TLR9 is expressed at the RNA levels in a series of 37 human glioblastomas (GBM) by quantitative PCR. TLR9 expression was detected at variable levels, which might suggest that some patients are more likely to benefit from treatment with CpG-ODN than others. No significant relationships between TLR9 expression and age, sex, tumor location, lymphocytes infiltration, oligodendroglial components or survival were found. TLR9 is unlikely to be expressed by tumor cells as no TLR9 expression was detected in pure human GBM xenografts. Immunocytochemistry studies showed TLR9 expression in some macrophages/microglial cells. The expression of TLR9 within human GBM strengthens the rationale for the utilization of CpG-ODN in this disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18253698     DOI: 10.1007/s11060-008-9536-2

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  23 in total

1.  Broad expression of Toll-like receptors in the human central nervous system.

Authors:  Malika Bsibsi; Rivka Ravid; Djordje Gveric; Johannes M van Noort
Journal:  J Neuropathol Exp Neurol       Date:  2002-11       Impact factor: 3.685

2.  Cultured astrocytes express toll-like receptors for bacterial products.

Authors:  Christal C Bowman; Amy Rasley; Susanne L Tranguch; Ian Marriott
Journal:  Glia       Date:  2003-09       Impact factor: 7.452

Review 3.  Microglia function in brain tumors.

Authors:  Jyoti J Watters; Jill M Schartner; Behnam Badie
Journal:  J Neurosci Res       Date:  2005-08-01       Impact factor: 4.164

4.  Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

Authors:  A F Carpentier; L Chen; F Maltonti; J Y Delattre
Journal:  Cancer Res       Date:  1999-11-01       Impact factor: 12.701

5.  Immunostimulatory CpG-DNA activates murine microglia.

Authors:  Alexander H Dalpke; Martin K-H Schäfer; Markus Frey; Stefan Zimmermann; Johannes Tebbe; Eberhard Weihe; Klaus Heeg
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

6.  Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells.

Authors:  F Takeshita; C A Leifer; I Gursel; K J Ishii; S Takeshita; M Gursel; D M Klinman
Journal:  J Immunol       Date:  2001-10-01       Impact factor: 5.422

7.  Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.

Authors:  Abdeljabar El Andaloussi; Adam M Sonabend; Yu Han; Maciej S Lesniak
Journal:  Glia       Date:  2006-11-01       Impact factor: 7.452

8.  Successful combination of local CpG-ODN and radiotherapy in malignant glioma.

Authors:  Yuxia Meng; Antoine F Carpentier; Lin Chen; Gilbert Boisserie; Jean-Marc Simon; Jean-Jacques Mazeron; Jean-Yves Delattre
Journal:  Int J Cancer       Date:  2005-10-10       Impact factor: 7.396

9.  The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides.

Authors:  Martin Henault; Linda N Lee; Glenn F Evans; Steven H Zuckerman
Journal:  J Immunol Methods       Date:  2005-05       Impact factor: 2.303

Review 10.  Primary brain tumours in adults.

Authors:  Anthony Behin; Khe Hoang-Xuan; Antoine F Carpentier; Jean-Yves Delattre
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

View more
  18 in total

Review 1.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

2.  Functionalized iron oxide nanoparticles for controlling the movement of immune cells.

Authors:  Ethan E White; Alex Pai; Yiming Weng; Anil K Suresh; Desiree Van Haute; Torkom Pailevanian; Darya Alizadeh; Ali Hajimiri; Behnam Badie; Jacob M Berlin
Journal:  Nanoscale       Date:  2015-05-07       Impact factor: 7.790

3.  CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production.

Authors:  Xiaoli Li; Dan Liu; Xin Liu; Weiwei Jiang; Weiying Zhou; Wei Yan; Yanyan Cen; Bin Li; Guanqun Cao; Guofu Ding; Xueli Pang; Jianguo Sun; Jiang Zheng; Hong Zhou
Journal:  Tumour Biol       Date:  2012-06-28

4.  Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy.

Authors:  Darya Alizadeh; Leying Zhang; Christine E Brown; Omar Farrukh; Michael C Jensen; Behnam Badie
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

5.  Toll-like receptor-9 expression is inversely correlated with estrogen receptor status in breast cancer.

Authors:  Arja Jukkola-Vuorinen; Eeva Rahko; Katri S Vuopala; Renee Desmond; Petri P Lehenkari; Kevin W Harris; Katri S Selander
Journal:  J Innate Immun       Date:  2008-08-28       Impact factor: 7.349

6.  TLR9 is critical for glioma stem cell maintenance and targeting.

Authors:  Andreas Herrmann; Gregory Cherryholmes; Anne Schroeder; Jillian Phallen; Darya Alizadeh; Hong Xin; Tianyi Wang; Heehyoung Lee; Christoph Lahtz; Piotr Swiderski; Brian Armstrong; Claudia Kowolik; Gary L Gallia; Michael Lim; Christine Brown; Behnam Badie; Stephen Forman; Marcin Kortylewski; Richard Jove; Hua Yu
Journal:  Cancer Res       Date:  2014-07-21       Impact factor: 12.701

7.  Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.

Authors:  Alexandre Carpentier; Philippe Metellus; Renata Ursu; Sarah Zohar; Francois Lafitte; Maryline Barrié; Yuxia Meng; Margaretha Richard; Christophe Parizot; Florence Laigle-Donadey; Guy Gorochov; Dimitri Psimaras; Marc Sanson; Annick Tibi; Olivier Chinot; Antoine F Carpentier
Journal:  Neuro Oncol       Date:  2010-01-25       Impact factor: 12.300

8.  Tumor infiltrating CD8+ T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinoma.

Authors:  Mikko Mella; Joonas H Kauppila; Peeter Karihtala; Petri Lehenkari; Arja Jukkola-Vuorinen; Ylermi Soini; Päivi Auvinen; Markku H Vaarala; Hanna Ronkainen; Saila Kauppila; Kirsi-Maria Haapasaari; Katri S Vuopala; Katri S Selander
Journal:  Oncoimmunology       Date:  2015-05-22       Impact factor: 8.110

9.  TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients.

Authors:  Chao Wang; Shouqiang Cao; Ying Yan; Qiao Ying; Tao Jiang; Ke Xu; Anhua Wu
Journal:  BMC Cancer       Date:  2010-08-10       Impact factor: 4.430

Review 10.  Advances in local therapy for glioblastoma - taking the fight to the tumour.

Authors:  Thomas S van Solinge; Lisa Nieland; E Antonio Chiocca; Marike L D Broekman
Journal:  Nat Rev Neurol       Date:  2022-03-11       Impact factor: 44.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.